Home Newsfeeds Cowen & Co. Downgrades Sumo Logic to Market Perform

Cowen & Co. Downgrades Sumo Logic to Market Perform

Cowen & Co. analyst Derrick Wood downgrades Sumo Logic (NASDAQ:SUMO) from Outperform to Market Perform.

byBenzinga Newsdesk

February 15, 2023

1 minute read

Cowen & Co. analyst Derrick Wood downgrades Sumo Logic (NASDAQ:SUMO) from Outperform to Market Perform.

Janney Montgomery Scott Initiates Coverage On Farmers National Banc with Neutral Rating, Announces Price Target of $14

By Benzinga Newsdesk

March 10, 9:13 AM

Janney Montgomery Scott analyst Daniel Cardenas initiates coverage on Farmers National Banc (NASDAQ:FMNB) with a Neutral rating and announces Price Target of $14.

FMNB

Medtronic, Merck, Williams Companies And More: CNBC’s ‘Final Trades’

By Priya Nigam

June 1, 8:21 AM

On CNBC’s "Halftime Report Final Trades," Anastasia Amoroso of JPMorgan Private Bank named iShares 7-10 Year Treasury Bond ETF (NASDAQ: IEF)

ESALY

Finch Therapeutics Announces Clinical Collaboration In Ulcerative Colitis With Brigham And Women’s Hospital And Updates To University Of Minnesota License Agreement

By Happy Mohamed

April 18, 4:12 PM

Finch Therapeutics Group, Inc. ("Finch", "Finch Therapeutics" or the "Company") (NASDAQ:FNCH), a microbiome technology company with a portfolio of intellectual property and microbiome

FNCH

Workhorse Discontinues C1000 Program, Escapes SEC Probe Without Enforcement Action

By Shivani Kumaresan

December 28, 11:44 AM

Workhorse Group Inc (NASDAQ:WKHS) said it is discontinuing the C1000 electric cargo van program, effective immediately, as it focuses its…

WKHS

Cowen & Co. Downgrades Sumo Logic to Market Perform

Related Posts

Janney Montgomery Scott Initiates Coverage On Farmers National Banc with Neutral Rating, Announces Price Target of $14

Medtronic, Merck, Williams Companies And More: CNBC’s ‘Final Trades’

Finch Therapeutics Announces Clinical Collaboration In Ulcerative Colitis With Brigham And Women’s Hospital And Updates To University Of Minnesota License Agreement

Workhorse Discontinues C1000 Program, Escapes SEC Probe Without Enforcement Action